GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

For those with major depression, there is a new treatment option - one that offers hope when patients are not responding to existing treatment. The ...

(NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced two ...

Spravato is the only drug derived from ketamine that is FDA-approved to treat a psychiatric condition. Some health clinics offer ketamine off-label to treat mental health conditions, including ...

Spravato is the only drug derived from ketamine that is FDA-approved to treat a psychiatric condition. Some health clinics offer ketamine off-label to treat mental health conditions, including ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the approval of Spravato for treatment-resistant depression. PE: How does ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...

Now, the FDA has also approved Spravato for treating adults with MDD who have not responded to at least two oral antidepressants. According to J&J, Spravato is an N-methyl-D-aspartate (NMDA ...

Drug is the first and only approved monotherapy for refractory major depressive disorder. (HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...